We used triple-color immunohistochemistry to evaluate Foxp3 and GzmB expression in CD4+ TILs in patients with advanced melanoma prior to therapy and 3 weeks post-treatment with ipilimumab and melphalan. This evidence concerns the gene FOXP3 and melanoma.